RARE DISEASE
Osteonecrosis of the jaw
Osteonecrosis of the jaw
Osteonecrosis of the jaw
Drug discovery
1
drug
With orphan designation
Overview
Osteonecrosis of the jaw (ONJ) is a rare but serious condition characterized by exposed, non-healing jawbone due to impaired vascular supply, often associated with antiresorptive (bisphosphonates, denosumab) or antiangiogenic therapies. It typically manifests as pain, exposed bone (>8 weeks), and infection, with highest incidence in oncology patients receiving high-dose IV therapy. Management involves staged approaches, emphasizing early diagnosis and multidisciplinary care to prevent progression [1][3][9][14].
Burden
Significantly impacts quality of life, causing chronic pain, dysphagia, and disfigurement [9][14].
Incidence rises with prolonged antiresorptive use: ~1% at 1 year, 3% at 3 years in cancer patients [10], reaching 9% in metastatic breast cancer cohorts [14].
Treatment costs and morbidity escalate in advanced stages due to complex surgical needs and prolonged antimicrobial therapy [4][7][12].
Therapies
Conservative: Antibiotics (e.g., penicillin, clindamycin), chlorhexidine rinses, and analgesia for early stages (0–2) [8][12][15].
Surgical: Debridement or resection for advanced non-responsive cases (stage 3), often combined with platelet-rich fibrin or laser therapy [7][16].
Preventive: Pre-therapy dental evaluation, minimally invasive procedures (e.g., root canals over extractions), and smoking cessation [1][5][9].
Categories: rare bone diseases, rare systemic and rheumatological diseases
Research Papers
2,041 drug discovery papers about Osteonecrosis of the jaw, with 3 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2,041 drug discovery papers about Osteonecrosis of the jaw, with 3 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-07-11 | Pharmacological and surgical predictors of postoperative healing in medication-related osteonecrosis of the jaw: A retrospective multicenter cohort study.
Failure to achieve postoperative healing after surgical treatment of medication-related osteonecrosis of the jaw (MRONJ) remains a clinical challenge. We aimed to investigate the independent predictors of postoperative nonhealing and to evaluate the impact of regenerative adjuncts. In a multicenter surgical cohort (2019-2025) of 531 patients with MRONJ, pharmacological, lesion level, and surgical factors were assessed using univariable testing, elastic net regularization for variable selection, and multivariable logistic regression. Postoperative nonhealing was defined as the need for additional surgical intervention or failure to achieve complete mucosal coverage, accompanied by clinical or radiographic evidence of persistent or progressive disease. Kaplan-Meier analysis was used to estimate nonhealing-free survival. The overall postoperative nonhealing rate was 18.5% (98/531). In the multivariable models, high-dose antiresorptive therapy (odds ratio [OR]: 2.94, 95% confidence interval [CI]: 1.70-5.06) and multiple-site lesions (OR: 2.29, 95% CI: 1.09-4.67) were independent risk factors for postoperative nonhealing, whereas intraoperative bone morphogenetic protein (BMP) use was associated with a lower risk of postoperative nonhealing (OR: 0.32, 95% CI: 0.20-0.52). The number needed to treat to prevent one postoperative nonhealing event was 5.3 (95% CI: 3.9-8.7) for BMP, and the number needed to harm was 4.4 (95% CI: 3.0-8.5) for high-dose therapy. Solitary maxillary lesions showed an insignificant protective effect. Antiangiogenic agents were associated with postoperative nonhealing in the univariate and elastic net analyses, but not in the final multivariable model. Neither treatment duration nor preoperative drug holiday was independently associated with postoperative nonhealing. The elastic net model showed acceptable discrimination (area under the curve [AUC]: 0.724), and the Kaplan-Meier curves were consistent with these findings. Postoperative nonhealing after surgical management of MRONJ was mainly associated with systemic pharmacological burden and lesion extent, whereas BMP application was associated with improved postoperative healing. These findings support further investigation of regenerative adjuncts and risk-adapted surgical management strategies.
2026-06-12 | Vitamin D Deficiency as a Context-Dependent Modifier of Osteonecrosis of the Jaw.
Osteonecrosis of the jaw (ONJ) is a multifactorial disorder characterized by impaired bone remodeling, vascular compromise, immune dysregulation, and mucosal barrier disruption. Although these mechanisms have been extensively investigated, they are often discussed separately, limiting an integrated understanding of ONJ pathogenesis. Vitamin D has emerged as a biologically relevant factor across these interconnected pathways, yet its role in ONJ remains incompletely defined. This narrative and hypothesis-generating review synthesizes current mechanistic, preclinical, observational, and clinical evidence regarding vitamin D biology and ONJ and proposes a vitamin D-centered vulnerability model in which vitamin D deficiency acts as a context-dependent modifier rather than a primary causal driver. Mechanistically, vitamin D deficiency may impair osteoblast function and mineralization, disrupt angiogenic responses, promote pro-inflammatory immune signaling, and compromise mucosal integrity, collectively creating a microenvironment susceptible to impaired healing and osteonecrosis. These effects are likely to vary across clinical settings, particularly in patients receiving antiresorptive or antiangiogenic therapies. Clinical and epidemiological studies have reported associations between low vitamin D status and increased ONJ risk or severity, while some observational studies suggest that vitamin D supplementation may be associated with improved outcomes in selected populations. However, current human evidence remains predominantly observational and subject to substantial heterogeneity and residual confounding, and direct randomized evidence is lacking. Overall, this framework provides an integrated perspective linking vitamin D biology to ONJ-related pathogenic processes and may support future mechanistic research, risk stratification, and supportive multidisciplinary management strategies. Nevertheless, the proposed model should be interpreted cautiously as hypothesis-generating and requires further validation in well-designed prospective studies and randomized controlled trials.
2026-06-04 | Amoxicillin bone penetration in patients with medication-related osteonecrosis of the jaw: A preliminary study.
Medication-related osteonecrosis of the jaw (MRONJ) is associated with altered bone perfusion and impaired drug delivery. This study aimed to compare amoxicillin exposure in plasma and bone tissue between patients with MRONJ and controls undergoing oral surgery. Twenty-seven patients treated with bisphosphonates or denosumab were enrolled between 2022 and 2024. Twelve patients with MRONJ were classified as cases, while fifteen were controls. Baseline characteristics, antibiotic regimens, and amoxicillin concentrations in plasma and bone tissue were considered. Drug concentrations were normalized for the administered dose. Samples with undetectable drug levels were excluded from analysis. Cases and controls were comparable in age, sex, body mass index, hematochemical parameters, and duration of antibiotic therapy. Median dose-adjusted plasma concentrations of amoxicillin were similar between cases (3.8 [2.8-4.5] mg/L/g) and controls (4.0 [3.0-4.8] mg/L/g amoxicillin, p = 0.533). In contrast, bone amoxicillin dose-adjusted concentrations were significantly lower in cases (0.9 [0.2-3.1] ng/mg/g amoxicillin) compared to controls (15.5 [8.7-17.9] ng/mg/g amoxicillin, p = 0.004). The bone-to-plasma ratio showed a non-significant trend toward lower values in MRONJ patients (49% vs 298%, p = 0.133). Despite similar systemic exposure, amoxicillin bone concentrations were significantly reduced in MRONJ patients, suggesting impaired local drug delivery potentially related to necrosis and poor vascularization. This exploratory study highlights the need for personalized antibiotic strategies in MRONJ management and provide a pharmacokinetic rationale for the reduced efficacy of beta-lactams in this clinical setting.
2026-07-11 | Pharmacological and surgical predictors of postoperative healing in medication-related osteonecrosis of the jaw: A retrospective multicenter cohort study.
Failure to achieve postoperative healing after surgical treatment of medication-related osteonecrosis of the jaw (MRONJ) remains a clinical challenge. We aimed to investigate the independent predictors of postoperative nonhealing and to evaluate the impact of regenerative adjuncts. In a multicenter surgical cohort (2019-2025) of 531 patients with MRONJ, pharmacological, lesion level, and surgical factors were assessed using univariable testing, elastic net regularization for variable selection, and multivariable logistic regression. Postoperative nonhealing was defined as the need for additional surgical intervention or failure to achieve complete mucosal coverage, accompanied by clinical or radiographic evidence of persistent or progressive disease. Kaplan-Meier analysis was used to estimate nonhealing-free survival. The overall postoperative nonhealing rate was 18.5% (98/531). In the multivariable models, high-dose antiresorptive therapy (odds ratio [OR]: 2.94, 95% confidence interval [CI]: 1.70-5.06) and multiple-site lesions (OR: 2.29, 95% CI: 1.09-4.67) were independent risk factors for postoperative nonhealing, whereas intraoperative bone morphogenetic protein (BMP) use was associated with a lower risk of postoperative nonhealing (OR: 0.32, 95% CI: 0.20-0.52). The number needed to treat to prevent one postoperative nonhealing event was 5.3 (95% CI: 3.9-8.7) for BMP, and the number needed to harm was 4.4 (95% CI: 3.0-8.5) for high-dose therapy. Solitary maxillary lesions showed an insignificant protective effect. Antiangiogenic agents were associated with postoperative nonhealing in the univariate and elastic net analyses, but not in the final multivariable model. Neither treatment duration nor preoperative drug holiday was independently associated with postoperative nonhealing. The elastic net model showed acceptable discrimination (area under the curve [AUC]: 0.724), and the Kaplan-Meier curves were consistent with these findings. Postoperative nonhealing after surgical management of MRONJ was mainly associated with systemic pharmacological burden and lesion extent, whereas BMP application was associated with improved postoperative healing. These findings support further investigation of regenerative adjuncts and risk-adapted surgical management strategies.
2026-06-12 | Vitamin D Deficiency as a Context-Dependent Modifier of Osteonecrosis of the Jaw.
Osteonecrosis of the jaw (ONJ) is a multifactorial disorder characterized by impaired bone remodeling, vascular compromise, immune dysregulation, and mucosal barrier disruption. Although these mechanisms have been extensively investigated, they are often discussed separately, limiting an integrated understanding of ONJ pathogenesis. Vitamin D has emerged as a biologically relevant factor across these interconnected pathways, yet its role in ONJ remains incompletely defined. This narrative and hypothesis-generating review synthesizes current mechanistic, preclinical, observational, and clinical evidence regarding vitamin D biology and ONJ and proposes a vitamin D-centered vulnerability model in which vitamin D deficiency acts as a context-dependent modifier rather than a primary causal driver. Mechanistically, vitamin D deficiency may impair osteoblast function and mineralization, disrupt angiogenic responses, promote pro-inflammatory immune signaling, and compromise mucosal integrity, collectively creating a microenvironment susceptible to impaired healing and osteonecrosis. These effects are likely to vary across clinical settings, particularly in patients receiving antiresorptive or antiangiogenic therapies. Clinical and epidemiological studies have reported associations between low vitamin D status and increased ONJ risk or severity, while some observational studies suggest that vitamin D supplementation may be associated with improved outcomes in selected populations. However, current human evidence remains predominantly observational and subject to substantial heterogeneity and residual confounding, and direct randomized evidence is lacking. Overall, this framework provides an integrated perspective linking vitamin D biology to ONJ-related pathogenic processes and may support future mechanistic research, risk stratification, and supportive multidisciplinary management strategies. Nevertheless, the proposed model should be interpreted cautiously as hypothesis-generating and requires further validation in well-designed prospective studies and randomized controlled trials.
2026-06-04 | Amoxicillin bone penetration in patients with medication-related osteonecrosis of the jaw: A preliminary study.
Medication-related osteonecrosis of the jaw (MRONJ) is associated with altered bone perfusion and impaired drug delivery. This study aimed to compare amoxicillin exposure in plasma and bone tissue between patients with MRONJ and controls undergoing oral surgery. Twenty-seven patients treated with bisphosphonates or denosumab were enrolled between 2022 and 2024. Twelve patients with MRONJ were classified as cases, while fifteen were controls. Baseline characteristics, antibiotic regimens, and amoxicillin concentrations in plasma and bone tissue were considered. Drug concentrations were normalized for the administered dose. Samples with undetectable drug levels were excluded from analysis. Cases and controls were comparable in age, sex, body mass index, hematochemical parameters, and duration of antibiotic therapy. Median dose-adjusted plasma concentrations of amoxicillin were similar between cases (3.8 [2.8-4.5] mg/L/g) and controls (4.0 [3.0-4.8] mg/L/g amoxicillin, p = 0.533). In contrast, bone amoxicillin dose-adjusted concentrations were significantly lower in cases (0.9 [0.2-3.1] ng/mg/g amoxicillin) compared to controls (15.5 [8.7-17.9] ng/mg/g amoxicillin, p = 0.004). The bone-to-plasma ratio showed a non-significant trend toward lower values in MRONJ patients (49% vs 298%, p = 0.133). Despite similar systemic exposure, amoxicillin bone concentrations were significantly reduced in MRONJ patients, suggesting impaired local drug delivery potentially related to necrosis and poor vascularization. This exploratory study highlights the need for personalized antibiotic strategies in MRONJ management and provide a pharmacokinetic rationale for the reduced efficacy of beta-lactams in this clinical setting.
Access all drug discovery articles and probability of success in trials forecasts:
Access all drug discovery articles and probability of success in trials forecasts:
Drug Discovery Landscape
1 orphan drug designation for Osteonecrosis of the jaw.
1 orphan drug designation for Osteonecrosis of the jaw.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
Recombinant human platelet derived growth factor BB | proteins | FDA | 2007-02-01 | — | Luitpold Pharmaceuticals, Inc. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.